https://finance.yahoo.com/news/senseonics-announces-positive-coverage-decision-110000272.html
Sens recently got insurance approval from anthem adding 45 million people that can now access Eversense CGM under insurance. This company has continually survived through hell and back with covid and then this recent recession and battling for FDA approval in the past. This company imo has shown exceptional management to survive and overcome these obstacles. Not only this but the technology is there and the product is there. This is the most accurate CGM out to date in terms of calculating blood sugar to the highest accuracy (yes better than dexcom). The way I look at it is this, this company currently has captured less than 1% of the diabetic market in the US. If they continue to grow and innovate there should be no reason why they don't capture more market share. Another interesting comparison to note is Dexcom's price per share back in the 08 recession got as low at $0.38 in Nov of 2008. Sens also had similar lows during covid and recently came back down into the $0.80 range before more than doubling recently on this news. I think even at $2 a share this company is a buy and will be a nice hold for the future. Their product pipeline is looking impeccable and they can eventually branch out laterally in the healthcare industry and make attempts at monitoring other variables other than glucose like blood chemistry variables or really any other blood component. I think the future can be very bright for a company like this. If we capitulate further and this recession does get worse keep this on the radar as a long term hold.
Leave a Reply